The present disclosure relates to implant tools and techniques for implanting implantable medical leads or other implantable components in extravascular locations.
Implantable cardiac defibrillator (ICD) systems are used to deliver high energy electrical pulses or shocks to a patient's heart to terminate life threatening arrhythmias, such as ventricular fibrillation. Traditional ICD systems include a housing that encloses a pulse generator and other electronics of the ICD and is implanted subcutaneously in the chest of the patient. The ICD is connected to one or more implantable medical electrical leads that are implanted within the heart, referred to herein as transvenous leads.
Traditional ICD systems that utilize transvenous leads may not be the preferable ICD system for all patients. For example, some patients with difficult vascular access precludes placement of transvenous leads. As another example, children and other younger patients may also be candidates for non-transvenous ICD systems. Moreover, transvenous leads may become fibrosed in the heart over time, making lead revision and extraction procedures challenging.
An extravascular ICD system may be preferred for some patients. An extravascular ICD system includes a lead (or leads) that are implanted extravascularly in the patient, e.g., outside and/or exclusive of the heart. As such, the extravascular ICD may eliminate the need to implant transvenous leads within the heart. Instead, the lead(s) may be implanted subcutaneously, substernally, or in other extravascular locations.
This application presents extravascular implant tools that utilize a bore-in mechanism to safely traverse the diaphragmatic attachments to access the substernal space. As will be described herein, using the bore-in mechanism may allow the implant tool to traverse the diaphragmatic attachments while controlling momentum of the implant tool after the traversal of the attachments. In this manner, the implant tool allows traversing of the diaphragmatic attachments with a reduced likelihood of damage to surrounding organs.
For example, this application provides an implant tool for implanting an implantable medical lead, implantable catheter or other implantable component within a patient. The implant tool includes an open channel delivery tool having a handle and a shaft adjacent the handle. The shaft has a proximal end, a distal end, and an open channel that extends from near the proximal end to the distal end. The implant tool also includes a bore-in mechanism configured to interact with the open channel delivery tool. In one example, the bore-in mechanism includes a handle and a helix extending from the handle, the handle and the helix forming a lumen that extends through the handle and the helix and is configured to receive the shaft of the open channel delivery tool. In another example, the bore-in mechanism comprises a handle and a screw extending from the handle, wherein the open channel of the delivery tool is sized to receive the screw of the bore-in mechanism.
In another example, this application provides a method for implanting a medical lead, a catheter or other implantable component, the method comprising screwing a bore-in mechanism into the diaphragmatic attachments of a patient, placing a shall of an open channel delivery tool adjacent to the bore-in mechanism, simultaneously pulling the bore-in mechanism while pushing the open channel delivery tool to traverse the diaphragmatic attachments.
In a further example, this application provides an implant tool for implanting an implantable medical lead, implantable catheter or other implantable component within a patient. The implant tool includes a bore-in mechanism having a handle and a helix extending from the handle. The handle and the helix form a lumen that extends through the handle and the helix. The implant tool also includes a tunneling tool that includes a shaft configured to be placed through the lumen of the bore-in mechanism. In one example, the tunneling tool comprises an open channel delivery tool that includes a handle and a shall adjacent the handle, the shaft having a proximal end, a distal end, and an open channel that extends from near the proximal end to the distal end. In another example, the tunneling tool comprises a rod and a sheath configured to be placed over the rod.
This summary is intended to provide an overview of the subject matter described in this disclosure. It is not intended to provide an exclusive or exhaustive explanation of the apparatus and methods described in detail within the accompanying drawings and description below. Further details of one or more examples are set forth in the accompanying drawings and the description below.
ICD 14 may include a housing that forms a hermetic seal that protects components of ICD 14. The housing of ICD 14 may be formed of a conductive material, such as titanium, or of a combination of conductive and non-conductive materials. The conductive material of the housing functions as a housing electrode. ICD 14 may also include a connector assembly (also referred to as a connector block or header) that includes electrical feedthroughs through which electrical connections are made between lead 16 and electronic components included within the housing. The housing may house one or more processors, memories, transmitters, receivers, sensors, sensing circuitry, therapy circuitry, power sources and other appropriate components.
ICD 14 is configured to be implanted in a patient, such as patient 12. ICD 14 is implanted extra-thoracically (e.g., subcutaneously or submuscularly) on the left midaxillary of patient 12. ICD 14 is on the left side of patient 12 outside the ribcage. ICD 14 may, in some instances, be implanted between the left posterior axillary line and the left anterior axillary line of patient 12. ICD 14 may, however, be implanted at other subcutaneous locations on patient 12 such as at a pectoral location or abdominal location.
Lead 16 includes an elongated lead body having a proximal end that includes a connector (not shown) configured to be connected to ICD 14 and a distal portion that includes electrodes 24, 28, and 30. The implant tools and techniques of this disclosure may be used to implant lead 16 as described herein. Lead 16 extends extra-thoracically, e.g., under skin and outside the ribcage (subcutaneously or submuscularly) from ICD 14 toward a center of the torso of patient 12, e.g., toward xiphoid process 20 of patient 12. At a location near the center of the torso, lead 16 bends or turns and extends superior intra-thoracically in a substernal location under/below sternum 22 and/or ribcage of the patient 12. In one example, the substernal location is substantially within anterior mediastinum 36 such that distal portion of lead 16 extends superior along the posterior side of the sternum within anterior mediastinum 36. Anterior mediastinum 36 may be viewed as being bounded laterally by pleurae 39, posteriorly by pericardium 38, and anteriorly by sternum 22. In some instances, the anterior wall of anterior mediastinum 36 may also be formed by the transversus thoracis and one or more costal cartilages. Anterior mediastinum 36 includes a quantity of loose connective tissue (such as areolar tissue), adipose tissue, some lymph vessels, lymph glands, substernal musculature (e.g., transverse thoracic muscle), the thymus gland, branches of the internal thoracic artery, and the internal thoracic vein. In one example, the distal portion of lead 16 may be implanted substantially within the loose connective tissue and/or substernal musculature of anterior mediastinum 36.
In other embodiments, the distal portion of lead 16 may be implanted in other intra-thoracic, non-vascular, extra-pericardial locations, including the gap, tissue, or other anatomical features around the perimeter of and adjacent to, but not attached to, the pericardium or other portion of heart 26 and not outside sternum 22 or ribcage (e.g., within the pleural cavity). As such, lead 16 may be implanted anywhere within the “substernal location” defined by the undersurface between the sternum and/or ribcage and the body cavity but not including the pericardium or other portion of heart 26. The substernal location may alternatively be referred to by the terms “retrosternal space” or “mediastinum” or “infrasternal” as is known to those skilled in the art and includes the anterior mediastinum 36. The substernal location may also include the anatomical region described in Baudoin, Y. P., et al., entitled “The superior epigastric artery does not pass through Larrey's space (trigonum stemocostale).” Surg. Radiol. Anat. 25.3-4 (2003): 259-62. In other words, the distal portion of lead 16 may be implanted in the region around the outer surface of heart 26, but not attached to heart 26.
The distal portion of lead 16 may be implanted substantially within anterior mediastinum 36 such that electrodes 24, 28, and 30 are located near a ventricle of heart 26. For instance, lead 16 may be implanted within anterior mediastinum 36 such that electrode 24 is located over a cardiac silhouette of one or both ventricles as observed via an anterior-posterior (AP) fluoroscopic view of heart 26. In one example, lead 16 may be implanted such that a therapy vector from electrode 24 to a housing electrode of ICD 14 is substantially across the ventricles of heart 26. The therapy vector may be viewed as a line that extends from a point on electrode 24, e.g., center of electrode 24, to a point on the housing electrode of ICD 14, e.g., center of the housing electrode. However, lead 16 may be positioned at other locations as long as the therapy vector between electrode 24 and the housing electrode is capable of defibrillating heart 26.
In the example illustrated in
The elongated lead body of lead 16 contains one or more elongated electrical conductors (not illustrated) that extend within the lead body from the connector at the proximal lead end to electrodes 24, 28, and 30 located along the distal portion of lead 16. The elongated lead body may have a generally uniform shape along the length of the lead body. In one example, the elongated lead body may have a generally tubular or cylindrical shape along the length of the lead body. The elongated lead body may have a diameter of between 3 and 9 French (Fr) in some instances. However, lead bodies of less than 3 Fr and more than 9 Fr may also be utilized. In another example, the distal portion (or all of) the elongated lead body may have a flat, ribbon or paddle shape. In this instance, the width across the flat portion of the flat, ribbon or paddle shape may be between 1 and 3.5 mm. Other lead body designs may be used without departing from the scope of this disclosure. The lead body of lead 16 may be formed from a non-conductive material, including silicone, polyurethane, fluoropolymers, mixtures thereof, and other appropriate materials, and shaped to form one or more lumens within which the one or more conductors extend. However, the techniques are not limited to such constructions.
The one or more elongated electrical conductors contained within the lead body of lead 16 may engage with respective ones of electrodes 24, 28, and 30. In one example, each of electrodes 24, 28, and 30 is electrically coupled to a respective conductor within the lead body. The respective conductors may electrically couple to circuitry, such as a therapy module or a sensing module, of ICD 14 via connections in connector assembly, including associated feedthroughs. The electrical conductors transmit therapy from a therapy module within ICD 14 to one or more of electrodes 24, 28, and 30 and transmit sensed electrical signals from one or more of electrodes 24, 28, and 30 to the sensing module within ICD 14.
Defibrillation electrode 24 is illustrated in
In other embodiments, however, defibrillation electrode 24 may be a flat ribbon electrode, paddle electrode, braided or woven electrode, mesh electrode, segmented electrode, directional electrode, patch electrode or other type of electrode besides an elongated coil electrode. In one example, defibrillation electrode 24 may be formed of a first segment and a second segment separated by a distance and having an electrode or a pair of electrodes (such as electrode 28 and/or 30 described below) located between the first and second defibrillation electrode segments. In one example, the segments may be coupled to the same conductor within the lead body such that the first and second segments function as a single defibrillation electrode. In other embodiments, defibrillation lead 16 may include more than one defibrillation electrode. For example, the first and second segments described above may be coupled to different conductors within the lead body such that the first and second segments function as separate defibrillation electrodes along the distal portion of lead 16. As another example, defibrillation lead 16 may include a second defibrillation electrode (e.g., second elongated coil electrode) near a proximal end of lead 16 or near a middle portion of lead 16.
Lead 16 also includes electrodes 28 and 30 located along the distal portion of lead 16. In the example illustrated in
In some instances, electrodes 28 and 30 of lead 16 may be shaped, oriented, designed or otherwise configured to reduce extracardiac stimulation. For example, electrodes 28 and 30 of lead 16 may be shaped, oriented, designed or otherwise configured to focus, direct or point electrodes 28 and 30 toward heart 26. In this manner, pacing pulses delivered via lead 16 are directed toward heart 26 and not outward toward skeletal muscle. For example, electrodes 28 and 30 of lead 16 may be partially coated or masked with a polymer (e.g., polyurethane) or another coating material (e.g., tantalum pentoxide) on one side or in different regions so as to direct the pacing signal toward heart 26 and not outward toward skeletal muscle.
ICD 14 may obtain sensed electrical signals corresponding with electrical activity of heart 26 via a combination of sensing vectors that include combinations of electrodes 28 and/or 30 and the housing electrode of LCD 14. For example, ICD 14 may obtain electrical signals sensed using a sensing vector between electrodes 28 and 30, obtain electrical signals sensed using a sensing vector between electrode 28 and the conductive housing electrode of ICD 14, obtain electrical signals sensed using a sensing vector between electrode 30 and the conductive housing electrode of LCD 14, or a combination thereof. In some instances. ICD 14 may even obtain sensed electrical signals using a sensing vector that includes defibrillation electrode 24.
ICD 14 analyzes the sensed electrical signals obtained from one or more of the sensing vectors of lead 16 to monitor for tachyarrhythmia, such as ventricular tachycardia or ventricular fibrillation. ICD 14 generates and delivers substernal electrical stimulation therapy, e.g., ATP, cardioversion or defibrillation shocks, and/or post-shock pacing in response to detecting tachycardia (e.g., VT or VF). In some instances, ICD 14 may generate and deliver bradycardia pacing in addition to ATP, cardioversion or defibrillation shocks, and/or post-shock pacing.
In the example illustrated in
Bore-in mechanism 60, which is illustrated in further detail in
Handle 62 and helix 64 form a lumen 66 that extends the entire length of bore-in mechanism 60. Helix 64 may be constructed of a metal, metal alloy, or rigid polymer. In one example, helix 64 may be formed from a wire. The wire may be of any of a variety of diameters. In one example, the wire diameter may be between approximately 0.035-0.100 inches. However, wires of other diameters may also be used without departing from the scope of this disclosure.
Helix 64 extends from handle 62 for a length L2 from handle to a distal end 68. Distal end 68 of helix 64 may be ground or otherwise formed to have sharp tip. Length L2 may be between approximately 1.5-3.5 inches. However, the actual length of helix 64 may be slightly longer than L2 as helix 64 may extend within handle 62 (as illustrated in
Shaft 54 of open channel delivery tool 50 and bore-in mechanism 60 are sized such that shaft 54 may pass through lumen 66. Thus, the diameter of lumen 66 (or the inner diameter (ID) of helix 64) may be formed to accommodate shaft 54 of open channel delivery tool 50. The ID of helix 64 may, for example, be between approximately 0.15-0.50 inches. However, IDs of smaller than 0.15 inches and larger than 0.50 inches may also be utilized. The outer diameter (OD) of helix 64 will depend on the diameter of the wire or other material used to form helix 64.
Handle 62 may be constructed of metal, alloy, polymer, or other material or combination of materials. Handle 62 may be sized and shaped to fit within a hand and be ergonomically comfortable. Handle 62 may, for example, have a length between 1.25-4.0 inches. However, handle 62 may have lengths greater and less than this range without departing from the scope of this disclosure. Handle 62 of
As described above, open channel delivery tool 50 includes a handle 52 and an elongate shaft 54 adjacent to handle 52, the shaft 54 defining an open channel 56 that extends from handle 52 to a distal end 58. Open channel 56 may extend the entire length of shaft 54 from handle 52 to distal end 58 in some embodiments. Shall 24 extends a length “L3” from handle 52 to distal end 58. The length L3 of shaft 54 may be determined based on the desired tunneling application. For example, shaft 54 may have a length between approximately 5 to 11 inches in some instances. However, other lengths may be appropriate for other desired applications.
Shaft 54 may have a relatively uniform thickness along the longitudinal length of shaft 54, e.g., along major axis “X” defined by open channel delivery tool 50. Alternatively, the thickness of the walls of shaft 54 may not be uniform along the length of shaft 54. For example, the walls of shall 54 may have an increased thickness toward distal end 58 compared to the proximal end of shaft 54. The increase in thickness toward distal end 58 may enable improved tunneling performance by increasing rigidness or stiffness at distal end 58 or by reducing interference with the tissue. Additionally, the increase thickness of distal end 58 may aid in shaping distal end to avoid coring, cutting, or puncturing of tissue, pleura, pericardium or other parts of patient 12. In other instances, distal end 58 and the proximal end near handle 52 of shaft 54 may have a greater thickness compared to the middle portion of shaft 54.
As illustrated in the cross sectional view of distal end 58 of shaft 54, taken perpendicular to the longitudinal length of shaft 54 from handle 52 to distal end 58 (e.g., orthogonal to the major axis X defined by open channel delivery tool 50), shaft 54 has a generally arc-shaped cross section that defines a generally arc-shaped open channel 56 (e.g., U-shaped and/or C-shaped). In other examples, however, the cross-section of shaft 54 and open channel 56 may be formed into any of a number of different shapes including, but not limited to, horseshoe-shape or other shape.
Open channel 56 has a depth, labeled “D” in
Open channel 56 also includes a width, labeled “W1” in
Shaft 54 may have the same cross section along the entire length of shaft 54. Alternatively, shaft 54 may have varying cross sections along portions of the length of shaft 54. For example, may have a more open cross-section, e.g., a U-shaped cross-section toward a proximal end of shaft 54 and a C-shaped cross-section along the mid and distal sections of the shaft 54. Other varying cross-sections may be utilized without departing from the scope of this disclosure. Shaft 54 may have a total cross-sectional thickness (T) of between approximately 0.080-0.450 inches and a total width (W2) of approximately 0.080-0.450 inches.
In the examples described above, open channel delivery tool 50 may be used to implant a particular sized lead such that a different implant tool (e.g., having a different sized open channel 56) may be selected depending on the size of the lead to be implanted, which may range from 2 French to 11 French. In further examples, a single open channel delivery tool 50 may be designed to deliver leads having a variety of different diameters. In this case, the depth D and width W of open channel 56 may be sized for delivery of the largest diameter lead for which tool 50 is designed.
Shaft 54 may have a relatively uniform thickness along the sides and bottom of the body of shaft 54. In other words, the walls along the sides and bottom of shaft 54 may all have about the same thickness. In another example, however, shaft 54 may have thicker walls along the sides of shaft 54 forming open channel 56 than along the bottom of shaft 54.
Elongate shaft 54 of open channel delivery tool 50 is formed such that it is stiff enough to be capable of being pushed through the tissue, muscle or other structure to form a path through the body. Shaft 54 may be made of a metal, polymer, or other material or combination of materials, e.g., metal and polymer. Such a tool could be extruded, molded, or inserted as part of a manufacturing process and would provide additional stiffness and malleability to the implant tool. In some instances, such as when shaft 54 is made of metal or a combination of metal and polymer, shaft 54 may be malleable. In other instances, shaft 54 of tool 50 may not be malleable, e.g., when shaft 54 is made of a molded polymer. In further instances, the implant tool may include a pre-formed or pre-shaped shaft 54. In this case, shaft 54 may be somewhat flexible while still being stiff enough to tunnel through tissue. The flexibility may allow a user to manipulate the tool slightly to control direction (e.g., steer) of the tunnel.
Handle 52 of open channel delivery tool 50 may also be made of a metal, alloy, polymer, or other material or combination of materials. Handle 52 and elongate shaft 54 may, in some instances, be constructed of the same material. For example, open channel delivery tool 50 may be formed of a single, unitary piece of material, such as metal or rigid polymer. In other instances, handle 52 and elongate shaft 54 may be constructed of different materials. In this case, handle 52 and shaft 54 may be formed of separate components that are attached together to form open channel delivery tool 50, e.g., via a two piece construction. For example, handle 52 may be made of polymer and shaft 54 may be made of metal and attached to handle 52 to form open channel delivery tool 50. Example metals or alloys from which handle 52 or shaft 54 may be constructed include, but are not limited to, stainless steel, titanium, titanium alloys, nickel-cobalt, and nickel-cobalt alloys. Example polymers may include, but are not limited to, acetal resin (e.g., DELRIN®), polyether ether ketone (PEEK), polycarbonate, polypropylene composites, and liquid-crystal polymer (LCP). In addition, lubricious fillers and coatings may be used to improve lubricity during tunneling and lead insertion. Such additives or coatings include, but are not limited to, siloxane, PTFE, and Foster ProPell™. Example radiopaque additives may include, without limitation, BaSO4, WC, and Bi2O3.
Distal end 58 of shaft 54 may be shaped to aid in tunneling through tissue or muscle. For example, distal end 58 of the shaft 54 may be tapered, angled, blunt, rounded, pointed, bent or otherwise shaped to enable a user to tunnel through tissue, ligaments, muscle or other structure without excess damage to surrounding tissue, piercing through the skin, or coring of the tissue.
Open channel delivery tool 50 and bore-in tool 60 may be used in conjunction with one another to safely traverse the diaphragmatic attachments. In one example, open channel delivery tool 50 and bore-in tool 60 may be used together to access the substernal space. As will be described below, using the tools in conjunction with one another may allow traversing the diaphragmatic attachments while controlling momentum of the shaft 54 of delivery tool 50 after the traversal of the attachments. In this manner, the implant tool allows traversing of the diaphragmatic attachments with a reduced likelihood of damage to surrounding organs.
Initially, an implanter or other user grips handle 62 and screws distal end 68 of helix 64 of bore-in tool 60 until the helix is firmly embedded into the diaphragmatic attachments near a center of the torso of patient 12 (e.g., just below the xiphoid process). In one example, distal end 68 of helix 64 does not traverse the diaphragmatic attachments. In another example, distal end 68 of helix 64 does traverse the diaphragmatic attachments.
After embedding helix 64 of bore-in mechanism 60 into the diaphragmatic attachments, distal end 58 of shaft 54 of open channel delivery tool 50 is inserted within lumen 66 of bore-in mechanism 60. In particular, distal end 58 of shaft 54 is placed within lumen 66 near handle 62 and advanced toward distal end 68 of helix 64. Bore-in mechanism 60 is pulled away from patient 12 while shaft 54 of open channel delivery tool 50 is advanced toward patient 12. By pulling bore-in mechanism 60 away from patient 12, the diaphragmatic attachments are pulled slightly away from chest cavity providing additional space for the distal end 58 of shaft 54 of open channel delivery tool 50 after it traverses the diaphragmatic attachments. In this manner, the implant tool allows traversing of the diaphragmatic attachments with a reduced likelihood of damage to surrounding organs.
After traversing the diaphragmatic attachments with shaft 54 of open channel delivery tool 50, bore-in mechanism 60 may either be left in place or may be unscrewed from the diaphragmatic attachments and moved to the proximal end of shaft 54. Distal end 58 of shaft 54 may be tunneled along the posterior side of the sternum to a desired location. Once at the desired location, the user may deliver an implantable electrical lead, such as defibrillation lead 16 of
Delivery tool 50 may be used to form a subcutaneous tunnel lateral between the center of the torso of the patient to a pocket on the left side of the patient. Lead 16 may be advance along channel 56 and delivery tool 50 may be removed leaving the proximal portion of lead 16 in place along the lateral path. This may be done before or after the substernal tunneling. The connector of lead 16 may be connected to the ICD.
In other embodiments, bore-in mechanism 60 may be integrated within delivery tool 50. For example, bore-in mechanism 60 may be permanently mounted on delivery tool 50 and capable of sliding along shaft 54. In such a case, deliver tool 50 and/or bore-in mechanism 60 may include some sort of locking mechanism by which bore-in mechanism may be fixed at the distal end during the boring and traversing process and then unlocked and slid to the proximal end of shaft 54 during the tunneling process. Moreover, delivery tool 50 may include some sort of trigger or other actuation mechanism for controllably moving shaft 54 through the lumen of bore-in mechanism 60 to controllably traverse the diaphragmatic attachments. The trigger may, for example, move shaft 54 a fixed distance relative to bore-in mechanism each time the trigger is actuated.
Additionally, although the implant tool of
Helical thread 78 is illustrated in
Handle 72 may be constructed of metal, metal alloy, polymer, or other material or combination of materials. Handle 72 may be sized and shaped to fit within a hand and be ergonomically comfortable. Handle 72 may, for example, have a length between 1.5-6.0 inches. However, handle 72 may have lengths greater and less than this range without departing from the scope of this disclosure. Handle 72 of
Shaft 54 of open channel delivery tool 50 and bore-in mechanism 70 are sized such that screw 74 of bore-in mechanism 70 fits within open channel 56 of delivery tool 50. Thus, screw 74 may be constructed to have an outer diameter that is less than the inner diameter of open channel 56.
Open channel delivery tool 50 and bore-in mechanism 70 may be used in conjunction with one another to safely traverse the diaphragmatic attachments. In one example, open channel deliver tool 50 and bore-in mechanism 70 may be used together to access the substernal space. As will be described below, using the tools in conjunction with one another may allow traversing the diaphragmatic attachments while controlling momentum of the tool after the traversal of the attachments. In this manner, the implant tool allows traversing of the diaphragmatic attachments with a reduced likelihood of damage to surrounding organs.
Initially, an implanter or other user grips handle 72 and turns to screw the distal end of screw 74 into the diaphragmatic attachments near a center of the torso of patient 12 (e.g., just below the xiphoid process). In one example, the distal end of screw 74 does not traverse the diaphragmatic attachments. In another example, the distal end of screw 74 does traverse the diaphragmatic attachments.
After embedding screw 74 of bore-in mechanism 70 into the diaphragmatic attachments, open channel 56 of delivery tool 50 is placed adjacent to the portion of screw 74 exiting the patient body such that screw 74 resides within open channel 56. As described above, shaft 76 and helical thread 78 are capable of being flexed or bent. Bore-in mechanism 70 is pulled away from patient 12 while shaft 54 of open channel delivery tool 50 is advanced toward patient 12. By pulling bore-in mechanism 70 away from patient 12, the diaphragmatic attachments are pulled slightly away from chest cavity providing additional space for the distal end 58 of shaft 54 of delivery tool 50 to traverse after it passes through the diaphragmatic attachments. In this manner, the implant tool allows traversing of the diaphragmatic attachments with a reduced likelihood of damage to surrounding organs.
After traversing the diaphragmatic attachments with shaft 54 of open channel delivery tool 50, bore-in mechanism 70 is unscrewed from the diaphragmatic attachments and removed from open channel 56 and the body of patient 12. Distal end 58 of shaft 54 may be tunneled along the posterior side of the sternum to a desired location. Once at the desired location, the user may deliver an implantable electrical lead, such as defibrillation lead 16 of
Delivery tool 50 may be used to form a subcutaneous tunnel lateral between the center of the torso of the patient to a pocket on the left side of the patient. Lead 16 may be advanced along channel 56 and delivery tool 50 may be removed leaving the proximal portion of lead 16 in place along the lateral path. This may be done before or after the substernal tunneling. The connector of lead 16 may be connected to the ICD.
In other embodiments, bore-in mechanism 70 may be integrated within delivery tool 50. For example, bore-in mechanism 70 may be permanently mounted within open channel 56 of delivery tool 50 and capable of sliding along open channel 56. To achieve such a configuration, bore-in mechanism 70 may not have a handle or the handle may be the same handle as the delivery tool 50. In such a case, delivery tool 50 and/or bore-in mechanism 70 may include some sort of locking mechanism by which bore-in mechanism 70 may be fixed at the distal end during the boring and traversing process and then unlocked and slid to the proximal end of open channel 56 during the tunneling process. Moreover, delivery tool 50 may include some sort of trigger or other actuation mechanism for controllably moving bore-in mechanism 70 along open channel 56 and/or for moving shaft 54 relative to bore-in mechanism 70 to controllably traverse the diaphragmatic attachments. The trigger may, for example, move shaft 54 a fixed distance relative to bore-in mechanism 70 each time the trigger is actuated. The inner surface of shaft 54 forming open channel 56 may be threaded along at least a portion of the shaft 54 to match the threading of screw 74.
Various examples have been described. These and other examples are within the scope of the following claims.
This application is a continuation of U.S. patent application Ser. No. 14/962,485, filed on Dec. 8, 2015, which claims the benefit of U.S. Provisional Patent Application No. 62/089,489, filed on Dec. 9, 2014. The entire content of each of these applications is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4030509 | Heilman et al. | Jun 1977 | A |
4146037 | Flynn et al. | Mar 1979 | A |
4207903 | O'neill | Jun 1980 | A |
4270549 | Heilman | Jun 1981 | A |
4280510 | O'Neill | Jul 1981 | A |
4291707 | Heilman et al. | Sep 1981 | A |
4424818 | Doring et al. | Jan 1984 | A |
4437475 | White | Mar 1984 | A |
4512351 | Pohndorf | Apr 1985 | A |
4538624 | Tarjan | Sep 1985 | A |
4644957 | Ricciardelli et al. | Feb 1987 | A |
4765341 | Mower et al. | Aug 1988 | A |
4832687 | Smith, III | May 1989 | A |
4874374 | Kousai et al. | Oct 1989 | A |
4921479 | Grayzel | May 1990 | A |
5009643 | Reich et al. | Apr 1991 | A |
5036854 | Schollmeyer et al. | Aug 1991 | A |
5125904 | Lee | Jun 1992 | A |
5147376 | Pianetti | Sep 1992 | A |
5176135 | Fain et al. | Jan 1993 | A |
5255691 | Otten | Oct 1993 | A |
5257973 | Villasuso | Nov 1993 | A |
5258003 | Ciaglia et al. | Nov 1993 | A |
5300106 | Dahl et al. | Apr 1994 | A |
5312355 | Lee | May 1994 | A |
5346502 | Estabrook et al. | Sep 1994 | A |
5364372 | Danks et al. | Nov 1994 | A |
5441504 | Pohndorf et al. | Aug 1995 | A |
5456699 | Armstrong | Oct 1995 | A |
5478329 | Ternamian | Dec 1995 | A |
5509924 | Paspa et al. | Apr 1996 | A |
5613953 | Pohndorf | Mar 1997 | A |
5667514 | Heller | Sep 1997 | A |
5671736 | Pettit et al. | Sep 1997 | A |
5690648 | Fogarty et al. | Nov 1997 | A |
5752937 | Otten et al. | May 1998 | A |
5755697 | Jones et al. | May 1998 | A |
5779715 | Tu | Jul 1998 | A |
5782841 | Ritz et al. | Jul 1998 | A |
5800398 | Hahnle et al. | Sep 1998 | A |
5853391 | Bell | Dec 1998 | A |
5871528 | Camps et al. | Feb 1999 | A |
5871532 | Schroeppel | Feb 1999 | A |
5944732 | Raulerson et al. | Aug 1999 | A |
5951518 | Licata et al. | Sep 1999 | A |
6032079 | KenKnight et al. | Feb 2000 | A |
6104957 | Alo et al. | Aug 2000 | A |
6122552 | Tockman et al. | Sep 2000 | A |
6159198 | Gardeski et al. | Dec 2000 | A |
6228052 | Pohndorf | May 2001 | B1 |
6278897 | Rutten et al. | Aug 2001 | B1 |
6283948 | McKernan et al. | Sep 2001 | B1 |
6324414 | Gibbons et al. | Nov 2001 | B1 |
6415187 | Kuzma et al. | Jul 2002 | B1 |
6436068 | Bardy | Aug 2002 | B1 |
6445954 | Olive et al. | Sep 2002 | B1 |
6544247 | Gardeski et al. | Apr 2003 | B1 |
6605094 | Mann | Aug 2003 | B1 |
6726617 | Schmidt | Apr 2004 | B1 |
6730083 | Freigang et al. | May 2004 | B2 |
6733500 | Kelley et al. | May 2004 | B2 |
6749574 | O'Keefe | Jun 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6772014 | Coe et al. | Aug 2004 | B2 |
6836687 | Kelley et al. | Dec 2004 | B2 |
6866044 | Bardy et al. | Mar 2005 | B2 |
6868291 | Booner et al. | Mar 2005 | B1 |
6887229 | Kurth | May 2005 | B1 |
7001396 | Glazier et al. | Feb 2006 | B2 |
7018384 | Skakoon | Mar 2006 | B2 |
7033326 | Pianca et al. | Apr 2006 | B1 |
7069083 | Finch et al. | Jun 2006 | B2 |
7076296 | Rissmann et al. | Jul 2006 | B2 |
7117039 | Manning et al. | Oct 2006 | B2 |
7151965 | Osypka | Dec 2006 | B2 |
7194309 | Ostroff et al. | Mar 2007 | B2 |
7195637 | Mika | Mar 2007 | B2 |
7218970 | Ley et al. | May 2007 | B2 |
7229450 | Chitre et al. | Jun 2007 | B1 |
7288096 | Chin | Oct 2007 | B2 |
7316667 | Linstrom et al. | Jan 2008 | B2 |
7322960 | Yamamoto et al. | Jan 2008 | B2 |
7361169 | Reilly | Apr 2008 | B2 |
7369899 | Malinowski et al. | May 2008 | B2 |
7389134 | Karicherla et al. | Jun 2008 | B1 |
7450997 | Pianca et al. | Nov 2008 | B1 |
7499758 | Cates et al. | Mar 2009 | B2 |
7499759 | Cates et al. | Mar 2009 | B2 |
7539542 | Malinowski | May 2009 | B1 |
7627375 | Bardy et al. | Dec 2009 | B2 |
7655014 | Ko et al. | Feb 2010 | B2 |
7736309 | Miller et al. | Jun 2010 | B2 |
7736330 | Bardy | Jun 2010 | B2 |
7758590 | Daniele et al. | Jul 2010 | B2 |
7765014 | Eversull et al. | Jul 2010 | B2 |
7837671 | Eversull et al. | Nov 2010 | B2 |
7846088 | Ness | Dec 2010 | B2 |
7890191 | Rutten et al. | Feb 2011 | B2 |
7930040 | Kelsch et al. | Apr 2011 | B1 |
7983765 | Doan et al. | Jul 2011 | B1 |
8012127 | Lieberman et al. | Sep 2011 | B2 |
8057486 | Hansen | Nov 2011 | B2 |
8060207 | Wallace et al. | Nov 2011 | B2 |
8065020 | Ley et al. | Nov 2011 | B2 |
8066702 | Rittman, III et al. | Nov 2011 | B2 |
8090451 | Tyson, Jr. | Jan 2012 | B2 |
8155755 | Flynn et al. | Apr 2012 | B2 |
8157813 | Ko et al. | Apr 2012 | B2 |
8260436 | Gerber et al. | Sep 2012 | B2 |
8271094 | Moffitt | Sep 2012 | B1 |
8280527 | Eckerdal et al. | Oct 2012 | B2 |
8340779 | Harris et al. | Dec 2012 | B2 |
8340781 | Konishi | Dec 2012 | B2 |
8355786 | Malinowski | Jan 2013 | B2 |
8364277 | Glukhovsky | Jan 2013 | B2 |
8386052 | Harris et al. | Feb 2013 | B2 |
8409233 | Chinn et al. | Apr 2013 | B1 |
8435208 | Bardy | May 2013 | B2 |
8442620 | Silipo et al. | May 2013 | B2 |
8447396 | Palti et al. | May 2013 | B2 |
8447398 | Bardy et al. | May 2013 | B2 |
8452421 | Thenuwara et al. | May 2013 | B2 |
8454552 | Bardy | Jun 2013 | B2 |
8478424 | Tronnes | Jul 2013 | B2 |
8478426 | Barker | Jul 2013 | B2 |
8942820 | Doerr et al. | Jan 2015 | B2 |
8986278 | Fung et al. | Mar 2015 | B2 |
9227053 | Bonde et al. | Jan 2016 | B2 |
9610436 | Seifert et al. | Apr 2017 | B2 |
10118027 | Seifert et al. | Nov 2018 | B2 |
10349978 | Seifert et al. | Jul 2019 | B2 |
10531893 | Seifert et al. | Jan 2020 | B2 |
10792490 | Seifert et al. | Oct 2020 | B2 |
11083491 | Drake et al. | Aug 2021 | B2 |
20020068912 | Merdan | Jun 2002 | A1 |
20020072712 | Nool et al. | Jun 2002 | A1 |
20020120277 | Hauschild | Aug 2002 | A1 |
20020120294 | Kroll | Aug 2002 | A1 |
20020143251 | Richardson | Oct 2002 | A1 |
20020147484 | Dahl et al. | Oct 2002 | A1 |
20030114908 | Flach | Jun 2003 | A1 |
20030233115 | Eversull et al. | Dec 2003 | A1 |
20040054388 | Osypka | Mar 2004 | A1 |
20040059348 | Geske et al. | Mar 2004 | A1 |
20040064147 | Struble | Apr 2004 | A1 |
20040087970 | Chu et al. | May 2004 | A1 |
20040102829 | Bonner et al. | May 2004 | A1 |
20040124389 | Phillips | Jul 2004 | A1 |
20040147940 | Crawford | Jul 2004 | A1 |
20040176781 | Lindstrom | Sep 2004 | A1 |
20040210293 | Bardy et al. | Oct 2004 | A1 |
20040236396 | Coe et al. | Nov 2004 | A1 |
20050049663 | Harris et al. | Mar 2005 | A1 |
20050119680 | Dykes | Jun 2005 | A1 |
20050131505 | Yokoyama | Jun 2005 | A1 |
20050288758 | Jones et al. | Dec 2005 | A1 |
20060041295 | Okypka | Feb 2006 | A1 |
20060116746 | Chin | Jun 2006 | A1 |
20060122676 | Ko et al. | Jun 2006 | A1 |
20060155250 | Endo et al. | Jul 2006 | A1 |
20060253181 | Schulman | Nov 2006 | A1 |
20060265047 | Dorn | Nov 2006 | A1 |
20070066977 | Assell et al. | Mar 2007 | A1 |
20070083217 | Eversull et al. | Apr 2007 | A1 |
20070100409 | Worley et al. | May 2007 | A1 |
20070173900 | Siegel | Jul 2007 | A1 |
20070203553 | Smits | Aug 2007 | A1 |
20070208402 | Helland et al. | Sep 2007 | A1 |
20070239241 | Tyson | Oct 2007 | A1 |
20070249992 | Bardy | Oct 2007 | A1 |
20080046056 | O'Connor | Feb 2008 | A1 |
20080097424 | Wizeman et al. | Apr 2008 | A1 |
20080103572 | Gerber | May 2008 | A1 |
20080132933 | Gerber | Jun 2008 | A1 |
20080132970 | Barolat | Jun 2008 | A1 |
20080167650 | Joshi et al. | Jul 2008 | A1 |
20080208133 | Lieberman et al. | Aug 2008 | A1 |
20080234717 | Bruszewski | Sep 2008 | A1 |
20080243219 | Malinowski et al. | Oct 2008 | A1 |
20080269716 | Bonde et al. | Oct 2008 | A1 |
20080269763 | Bonde et al. | Oct 2008 | A1 |
20090018603 | Mitelberg et al. | Jan 2009 | A1 |
20090043373 | Arnault De | Feb 2009 | A1 |
20090069750 | Schraga | Mar 2009 | A1 |
20090076521 | Hansen | Mar 2009 | A1 |
20090157091 | Buysman | Jun 2009 | A1 |
20090222021 | Chang | Sep 2009 | A1 |
20090259283 | Brandt et al. | Oct 2009 | A1 |
20090264780 | Schilling | Oct 2009 | A1 |
20100016935 | Strandberg et al. | Jan 2010 | A1 |
20100030227 | Kast et al. | Feb 2010 | A1 |
20100030228 | Havel | Feb 2010 | A1 |
20100056858 | Mokelke et al. | Mar 2010 | A1 |
20100094252 | Wengreen et al. | Apr 2010 | A1 |
20100113963 | Smits et al. | May 2010 | A1 |
20100125194 | Bonner et al. | May 2010 | A1 |
20100137879 | Ko et al. | Jun 2010 | A1 |
20100152747 | Padiy et al. | Jun 2010 | A1 |
20100198149 | Fox | Aug 2010 | A1 |
20100198229 | Olomutzki et al. | Aug 2010 | A1 |
20100217298 | Bardy | Aug 2010 | A1 |
20100217301 | Bardy | Aug 2010 | A1 |
20100249696 | Bardy | Sep 2010 | A1 |
20100268024 | Brannon | Oct 2010 | A1 |
20100305428 | Bonner et al. | Dec 2010 | A1 |
20100318098 | Lund et al. | Dec 2010 | A1 |
20110009877 | Thenuwara et al. | Jan 2011 | A1 |
20110009933 | Barker | Jan 2011 | A1 |
20110022057 | Eigler et al. | Jan 2011 | A1 |
20110190786 | Gerber et al. | Aug 2011 | A1 |
20110224680 | Barker | Sep 2011 | A1 |
20110224681 | McDonald | Sep 2011 | A1 |
20110257660 | Jones et al. | Oct 2011 | A1 |
20120016377 | Geroy | Jan 2012 | A1 |
20120029335 | Sudam et al. | Feb 2012 | A1 |
20120078266 | Tyson, Jr. | Mar 2012 | A1 |
20120089153 | Christopherson et al. | Apr 2012 | A1 |
20120097174 | Spotnitz et al. | Apr 2012 | A1 |
20120191106 | Ko et al. | Jul 2012 | A1 |
20120209283 | Zhu | Aug 2012 | A1 |
20120209285 | Barker et al. | Aug 2012 | A1 |
20120277761 | Boling et al. | Nov 2012 | A1 |
20120290057 | Boling et al. | Nov 2012 | A1 |
20120302915 | Lee | Nov 2012 | A1 |
20130079693 | Ranky et al. | Mar 2013 | A1 |
20130103049 | Bonde | Apr 2013 | A1 |
20130110159 | Litvack et al. | May 2013 | A1 |
20130158564 | Harris et al. | Jun 2013 | A1 |
20130238067 | Baudino | Sep 2013 | A1 |
20130253260 | Lund et al. | Sep 2013 | A1 |
20130281772 | Fridez et al. | Oct 2013 | A1 |
20130296879 | Lazeroms et al. | Nov 2013 | A1 |
20130317583 | Pianca | Nov 2013 | A1 |
20140012292 | Stewart | Jan 2014 | A1 |
20140039264 | Heiman | Feb 2014 | A1 |
20140073926 | Rajendran et al. | Mar 2014 | A1 |
20140148786 | Milo | May 2014 | A1 |
20140163655 | Chitre | Jun 2014 | A1 |
20140194924 | Tegels | Jul 2014 | A1 |
20140276927 | Barker | Sep 2014 | A1 |
20140330208 | Christie et al. | Nov 2014 | A1 |
20140336581 | Collin | Nov 2014 | A1 |
20150032142 | Silvestro | Jan 2015 | A1 |
20150105793 | Cole | Apr 2015 | A1 |
20150133951 | Siefert et al. | May 2015 | A1 |
20150133952 | Seifert et al. | May 2015 | A1 |
20150133953 | Siefert et al. | May 2015 | A1 |
20150133954 | Siefert et al. | May 2015 | A1 |
20150216519 | Tang et al. | Aug 2015 | A1 |
20150313633 | Gross et al. | Nov 2015 | A1 |
20160157890 | Drake et al. | Jun 2016 | A1 |
20160158530 | Drake et al. | Jun 2016 | A1 |
20160175008 | Seifert et al. | Jun 2016 | A1 |
Number | Date | Country |
---|---|---|
2364868 | Feb 2000 | CN |
101072601 | Nov 2007 | CN |
101502699 | Aug 2009 | CN |
101742975 | Jun 2010 | CN |
102202726 | Sep 2011 | CN |
102716543 | Oct 2012 | CN |
102943352 | Feb 2013 | CN |
103096838 | May 2013 | CN |
103096963 | May 2013 | CN |
103157181 | Jun 2013 | CN |
103635225 | Mar 2014 | CN |
0517494 | Dec 1992 | EP |
9720530 | Jun 1997 | WO |
2001023035 | Apr 2001 | WO |
2004073506 | Sep 2004 | WO |
2010045228 | Apr 2010 | WO |
2012032147 | Mar 2012 | WO |
2012106088 | Aug 2012 | WO |
2013076213 | May 2013 | WO |
Entry |
---|
Avogadros Lab Supply Inc., Catalog; Scoopula with Beech Wood Handle, can be found on-line at http://www.avogadro-lab-supply.com/search.php, accessed Oct. 6, 2013, 1 page. |
Bielefeld et al., “Thoracoscopic Placement of Implantable Cardioverter-Defibrillator Patch Leads in Sheep,” Circulation; Nov. 1993, vol. 88, Part 2; 5 pages. |
Bolling et al., “Automatic Internal Cardioverter Defibrillator: A Bridge to Heart Transplantation,” Heart Lung Transplantation, Abstract Only, Jul.-Aug. 1991, 1 page. |
Boston Scientific, “Emblem S-ICD Subcutaneous Electrode Insertion Tool”, Model 4711 User Manual, Feb. 1, 2015, accessed from https://web.archive.org/web/20151025171513/https://www.bostonscientific.com/manuals/manuals/landing-page/US-english.html, 28 pp. |
(PCT/US2015/064599) PCT International Preliminary Report on Patentability, Mailed Jun. 13, 2017, 8 pages. |
(PCT/US2015/064599) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, Mailed Mar. 15, 2016, 13 pages. |
Cigna et al., “A New Technique for Substernal Colon Transposition with a Brest Dissector: Report of 39 Cases,” Journal of Plastic, Reconstructive and Aesthetic Surgery, Apr. 2006; 59, 4 pages. |
Damiano, “Implantation of Cardioverter Defibrillators in the Post-Sternotomy Patient,” The Annals of Thoracic Surger, Jun. 1, 1992; 53: pp. 978-983. |
Ely et al., “Thorasoscopic Implantation of the Implantable Cardioverter Defibrillator,” Minimally Invasive Techniques; (Can be found on the World-Wide Web at http://chestioumal.chestpubs.org on May 6, 2013); dated Jan. 1993; 2 pages. |
Frame et al., “Long-Term Stability of Defibrillation Thresholds with Intrapericardial Defibrillator Patches” Pacing and Clinical Electrophysiology, Jan. 1993, Part II, vol. 16, 6 pages. |
Greatbatch Medical, OptiSeal Valved Peelable Introducer Brochure,, 2 pp. (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 2010, is sufficiently earlier than the effective U.S. filing date so that the particular month of publication is not in issue). |
Harman et al., “Differences in the Pathological Changes in Dog' Hearts After Defibrillation with Extrapericardial Paddles and Implanted Defibrillator Electrodes,” Journal of Pacing and Clinical Electrophysiology, Feb. 1991; vol. 14; Part 2; 5 pages. |
Karwande et al., Bilateral Anterior Thoracotomy for Automatic Implantable Cardioverter Defibrillator Placement in Patients with Previous Sternotomy, The Annals of Thoracic Surgery, Oct. 1992; 54(4); 3 pages. |
Lawrie et al., “Right Mini-Thoracotomy: An Adjunct to Left Subcostal Automatic Implantable Cardioverter Defibrillator Implantation,” The Annals of Thoracic Surgery; May 1989; 47; 4 pages. |
Lemmer, “Defibrillator Patch Constriction, Letter to the Editor,” The Annals of Thoracic Surgery, 1996 (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 1996, is sufficiently earlier than the effective U.S. filing date so that the particular month of publication is not in issue), 1 page. |
Medtronic, Inc. 6996SQ Subcutanesous, Unipolar Lead with Defibrillation Coil Electrode, Technical Manual, 2012 (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 2012, is sufficiently earlier than the effective U.S. filing date so that the particular month of publication is not in issue) 22 pages. |
Medtronic, Inc. 6996T Tunneling Tool, Technical Manual, 2011 ((Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 2011, is sufficiently earlier than the effective U.S. filing date so that the particular month of publication is not in issue)12 pages. |
Mitchell et al., “Experience with an Implantable Tiered Therapy Device Incorporating Antitachycardia Pacing and Cardioverter/Defibrillator Therapy,” Thoracic and Cardiovascular Surgery, Abstract Only, Mar. 1993, 1 page. |
Molina et al, “An Epicardial Subxiphoid Implantable Defibrillator Lead: Superior Effectiveness After Failure of Stndard Implants”, From the Department of Surgery, Division of Cardiovascular and Thoracic Surgery and the Department of Medicine, Cardiac Arrhythmia Center, University of Minnesota Medical School, Minneapolis, Minnesota, Pace, vol. 27, Nov. 2004, 7 pages. |
Obadia et al., “New Approach for Implantation of Automatic Defibrillators Using Videothoracoscopy,” Journal Ann Cardiol Angeiol (Paris); Sep. 1994; 43 (7) Abstract Only, 1 page. |
Obadia et al., “Thorasoscopic Approach to Implantable Cardioverter Defibrillator Patch Electrode Implantation,” Pacing and Clinical Electrophysiology: Jun. 1996; vol. 19; 6 pages. |
Pebax Product Brochure, 14 pages and can be found on-line at http://www.pebax.com/export/sites/pebax/content/medias/downloads/literature/pebax-product-rang-brouchure.pdf, Accessed Feb. 28, 2014, 14 pages. |
Piccione et al., “Erosion of Extrapericardial Implantable Cardioverter Defibrillator Patch Through the Gastic Funds with Fistulous Tract Information,” Cardiology in Review, Nov./Dec. 2006; 14, e21-e23 pages. |
Prosecution History from U.S. Appl. No. 14/193,573, dated May 2, 2014 through Jul. 3, 2020, 195 pp. |
Prosecution History from U.S. Appl. No. 14/193,634 dated May 16, 2016 through Jul. 8, 2020, 355 pp. |
Prosecution History from U.S. Appl. No. 14/196,298, dated Jul. 16, 2015 through Sep. 3, 2019, 278 pp. |
Prosecution History from U.S. Appl. No. 14/196,443, dated Mar. 4, 2014 through Dec. 9, 2016, 109 pp. |
Prosecution History from U.S. Appl. No. 14/962,485, dated Jul. 13, 2017 through Apr. 1, 2021, 247 pp. |
Prosecution History from U.S. Appl. No. 14/962,541, dated Jan. 5, 2018 through Oct. 24, 2020, 198 pp. |
Prosecution History from U.S. Appl. No. 14/973,800 dated Sep. 19, 2017 through Apr. 17, 2019, 95 pp. |
Quigley et al., “Migration of an Automatic Implantable Cardioverter-Defibrillator Patch Causing Massive Hemothorax,” Journal Texas Heart Institute, Nov. 1, 1996; vol. 23, 4 pages. |
Seifert et al., “Open Channel Implant Tools”, Chinese Patent Application No. 201480072593.0, Third Office Action Mailed Mar. 29, 2019, 5 pages. |
Shapira et al., A Simplified Method for Implantation of Automatic Cardioverter Defibrillator in Patients with Previous Cardiac Surgery, Pacing and Clinical Electrophysiology, Part 1, Jan. 1996, vol. 16; 6 pages. |
Steinke et al., Subepicardial Infarction, Myocardial Impression, and Ventricular Penetration by Sutureless Electrode and Leads, Chest; 70: Jul. 1, 1976, 2 pages. |
Tung et al., “Minimal Invasive Extra Cardiac Placement of High Voltage Defibrillator Leads”, Poster 3; S200 Abstract, P0-3-4; St. Paul Hospital, Vancouver, British Columbia, Canada, Oct. 2007, 1 pages. |
U.S. Appl. No. 17/062,183, filed Oct. 2, 2020, naming inventors Seifert et al. |
Vyhmeister et al., “Simple Approach for Extrapericardial Placement of Defibrillator Patches via Median Sternotomy,” The Annals of Thoracic Surgery; Dec. 1994; 57: 4 pages. |
Response to Office Action dated Aug. 16, 2023 from U.S. Appl. No. 17/062,183, filed Nov. 15, 2023, 10 pp. |
Office Action from U.S. App. No. 17/062,183 dated Aug. 16, 2023, 18 pp. |
Advisory Action from U.S. Appl. No. 17/062,183 dated Mar. 28, 2024, 2 pp. |
Final Office Action from U.S. Appl. No. 17/062,183 dated Jan. 17, 2024, 13 pp. |
Response to Final Office Action dated Jan. 17, 2024 from U.S. Appl. No. 17/062,183, filed Mar. 14, 2024, 10 pp. |
Office Action from U.S. Appl. No. 17/062,183 dated Jun. 21, 2024, 13 pp. |
Number | Date | Country | |
---|---|---|---|
20220061886 A1 | Mar 2022 | US |
Number | Date | Country | |
---|---|---|---|
62089489 | Dec 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14962485 | Dec 2015 | US |
Child | 17397276 | US |